TY - JOUR
T1 - Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma
AU - Ishida, Joji
AU - Kurozumi, Kazuhiko
AU - Ichikawa, Tomotsugu
AU - Otani, Yoshihiro
AU - Onishi, Manabu
AU - Fujii, Kentaro
AU - Shimazu, Yosuke
AU - Oka, Tetsuo
AU - Shimizu, Toshihiko
AU - Date, Isao
N1 - Funding Information:
We thank Dr. Koichi Ichimura in the Division of Brain Tumor Translational Research, National Cancer Center Research Institute, for advice concerning the MGMT pyrosequencing assay, and M. Arao and N. Uemori for their technical assistance. This study was supported by Grants-in-aid of Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology to K.K. (Nos. 20890133 and 21791364), and T.I. (Nos. 19591675 and 22591611).
Publisher Copyright:
© 2015, The Japan Society of Brain Tumor Pathology.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Recently, research efforts in identifying prognostic molecular biomarkers for malignant glioma have intensified. Cysteine-rich protein 61 (CCN1) is one of the CCN family of matricellular proteins that promotes cell growth and angiogenesis in cancers through its interaction with several integrins. In this study, we investigated the relationships among CCN1, O6-methylguanine-DNA methyltransferase expression, the tumor removal rate, and prognosis in 46 glioblastoma patients treated at the Okayama University Hospital. CCN1 expression was high in 31 (67 %) of these patients. The median progression-free survival (PFS) and overall survival (OS) times of patients with high CCN1 expression was significantly shorter than those of patients with low CCN1 expression (p < 0.005). In a multivariate Cox analysis, CCN1 proved to be an independent prognostic factor for patient survival [PFS, hazard ratio (HR) = 3.53 (1.55–8.01), p = 0.003 and OS, HR = 3.05 (1.35–6.87), p = 0.007]. Moreover, in the 31 patients who underwent gross total resection, the PFS and OS times of those with high CCN1 expression were significantly shorter than those with low CCN1 expression. It was concluded that CCN1 might emerge as a significant prognostic factor regarding the prognosis of glioblastoma patients.
AB - Recently, research efforts in identifying prognostic molecular biomarkers for malignant glioma have intensified. Cysteine-rich protein 61 (CCN1) is one of the CCN family of matricellular proteins that promotes cell growth and angiogenesis in cancers through its interaction with several integrins. In this study, we investigated the relationships among CCN1, O6-methylguanine-DNA methyltransferase expression, the tumor removal rate, and prognosis in 46 glioblastoma patients treated at the Okayama University Hospital. CCN1 expression was high in 31 (67 %) of these patients. The median progression-free survival (PFS) and overall survival (OS) times of patients with high CCN1 expression was significantly shorter than those of patients with low CCN1 expression (p < 0.005). In a multivariate Cox analysis, CCN1 proved to be an independent prognostic factor for patient survival [PFS, hazard ratio (HR) = 3.53 (1.55–8.01), p = 0.003 and OS, HR = 3.05 (1.35–6.87), p = 0.007]. Moreover, in the 31 patients who underwent gross total resection, the PFS and OS times of those with high CCN1 expression were significantly shorter than those with low CCN1 expression. It was concluded that CCN1 might emerge as a significant prognostic factor regarding the prognosis of glioblastoma patients.
KW - CCN1
KW - Glioma
KW - MGMT
KW - Prognostic marker
UR - http://www.scopus.com/inward/record.url?scp=84945491162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945491162&partnerID=8YFLogxK
U2 - 10.1007/s10014-015-0227-3
DO - 10.1007/s10014-015-0227-3
M3 - Article
C2 - 26201842
AN - SCOPUS:84945491162
SN - 1433-7398
VL - 32
SP - 245
EP - 252
JO - Brain Tumor Pathology
JF - Brain Tumor Pathology
IS - 4
ER -
